Sino Biopharmaceutical Limited, an investment holding company, together with its subsidiaries, operates as a research and development pharmaceutical conglomerate in the People’s Republic of China. More Details
Outstanding track record with adequate balance sheet.
Share Price & News
How has Sino Biopharmaceutical's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 1177 is not significantly more volatile than the rest of Hong Kong stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: 1177's weekly volatility (5%) has been stable over the past year.
7 Day Return
1 Year Return
Return vs Industry: 1177 underperformed the Hong Kong Pharmaceuticals industry which returned 21.2% over the past year.
Return vs Market: 1177 underperformed the Hong Kong Market which returned 25.9% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Sino Biopharmaceutical's share price compared to the market and industry in the last 5 years?
Simply Wall St News
4 days ago | Simply Wall StSino Biopharmaceutical Limited's (HKG:1177) Recent Stock Performance Looks Decent- Can Strong Fundamentals Be the Reason?
2 weeks ago | Simply Wall StVP & Executive Director Hsin Tse Just Bought A Handful Of Shares In Sino Biopharmaceutical Limited (HKG:1177)
4 weeks ago | Simply Wall StSino Biopharmaceutical (HKG:1177) Seems To Use Debt Quite Sensibly
Is Sino Biopharmaceutical undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: 1177 (HK$8.3) is trading below our estimate of fair value (HK$11.05)
Significantly Below Fair Value: 1177 is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: 1177 is poor value based on its PE Ratio (33.8x) compared to the Hong Kong Pharmaceuticals industry average (14.3x).
PE vs Market: 1177 is poor value based on its PE Ratio (33.8x) compared to the Hong Kong market (11.7x).
Price to Earnings Growth Ratio
PEG Ratio: 1177 is poor value based on its PEG Ratio (3.3x)
Price to Book Ratio
PB vs Industry: 1177 is overvalued based on its PB Ratio (6.9x) compared to the HK Pharmaceuticals industry average (1.3x).
How is Sino Biopharmaceutical forecast to perform in the next 1 to 3 years based on estimates from 23 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 1177's forecast earnings growth (10.3% per year) is above the savings rate (1.5%).
Earnings vs Market: 1177's earnings (10.3% per year) are forecast to grow slower than the Hong Kong market (19.3% per year).
High Growth Earnings: 1177's earnings are forecast to grow, but not significantly.
Revenue vs Market: 1177's revenue (12.5% per year) is forecast to grow slower than the Hong Kong market (12.7% per year).
High Growth Revenue: 1177's revenue (12.5% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 1177's Return on Equity is forecast to be high in 3 years time (20.4%)
How has Sino Biopharmaceutical performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 1177 has high quality earnings.
Growing Profit Margin: 1177's current net profit margins (15.4%) are higher than last year (11.5%).
Past Earnings Growth Analysis
Earnings Trend: 1177's earnings have grown by 17.9% per year over the past 5 years.
Accelerating Growth: 1177's earnings growth over the past year (37%) exceeds its 5-year average (17.9% per year).
Earnings vs Industry: 1177 earnings growth over the past year (37%) exceeded the Pharmaceuticals industry 9.2%.
Return on Equity
High ROE: 1177's Return on Equity (22.8%) is considered high.
How is Sino Biopharmaceutical's financial position?
Financial Position Analysis
Short Term Liabilities: 1177's short term assets (CN¥21.8B) exceed its short term liabilities (CN¥10.4B).
Long Term Liabilities: 1177's short term assets (CN¥21.8B) exceed its long term liabilities (CN¥13.9B).
Debt to Equity History and Analysis
Debt Level: 1177's debt to equity ratio (54.4%) is considered high.
Reducing Debt: 1177's debt to equity ratio has increased from 15.8% to 54.4% over the past 5 years.
Debt Coverage: 1177's debt is well covered by operating cash flow (39.4%).
Interest Coverage: 1177 earns more interest than it pays, so coverage of interest payments is not a concern.
What is Sino Biopharmaceutical current dividend yield, its reliability and sustainability?
Current Dividend Yield
Upcoming Dividend Payment
Dividend Yield vs Market
Notable Dividend: 1177's dividend (0.96%) isn’t notable compared to the bottom 25% of dividend payers in the Hong Kong market (1.86%).
High Dividend: 1177's dividend (0.96%) is low compared to the top 25% of dividend payers in the Hong Kong market (5.89%).
Stability and Growth of Payments
Stable Dividend: 1177's dividend payments have been volatile in the past 10 years.
Growing Dividend: 1177's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its reasonably low payout ratio (29.8%), 1177's dividend payments are well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: 1177's dividends in 3 years are forecast to be well covered by earnings (29.5% payout ratio).
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Yi Li (58 yo)
Mr. Yi Li serves as Chief Executive Officer and Executive Director at Sino Biopharmaceutical Limited since August 19, 2020. He joined J.P. Morgan China in October 2014 as chairman and chief executive offic...
CEO Compensation Analysis
Compensation vs Market: Yi's total compensation ($USD3.58M) is above average for companies of similar size in the Hong Kong market ($USD895.42K).
Compensation vs Earnings: Insufficient data to compare Yi's compensation with company performance.
Experienced Board: 1177's board of directors are considered experienced (6.2 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: 1177 insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Sino Biopharmaceutical Limited's company bio, employee growth, exchange listings and data sources
- Name: Sino Biopharmaceutical Limited
- Ticker: 1177
- Exchange: SEHK
- Founded: 2000
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: HK$155.882b
- Shares outstanding: 18.78b
- Website: https://www.sinobiopharm.com
Number of Employees
- Sino Biopharmaceutical Limited
- Office Tower
- Unit 09, 41st Floor, Room 4109
- Wan Chai
- Hong Kong
Sino Biopharmaceutical Limited, an investment holding company, together with its subsidiaries, operates as a research and development pharmaceutical conglomerate in the People’s Republic of China. It opera...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/06/14 10:36|
|End of Day Share Price||2021/06/11 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.